Streetbeat News

Analyst Ratings

NXGN

Truist Securities analyst Jailendra Singh maintains a Hold rating on NextGen Healthcare (NASDAQ:NXGN) and lowers the price target from $22 to $18.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 2:16 pm

RBC

Truist Securities analyst Michael Ciarmoli maintains a Buy rating on RBC Bearings (NYSE:RBC) and raises the price target from $252 to $263.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 2:15 pm

TENX

Zacks Small-Cap Research has set a $5 price valuation for Tenax Therapeutics (TENX), a specialty pharmaceutical company focused on developing and commercializing products for critical care patients.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 2:14 pm

FL

Guggenheim analyst Robert Drbul maintains a Buy rating on Foot Locker (NYSE:FL) but lowers the price target from $60 to $50.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 2:13 pm

FLO

Deutsche Bank analyst Steve Powers maintains a Hold rating on Flowers Foods (NYSE:FLO) and lowers the price target from $26 to $24.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 2:10 pm

NKE

Nike's shares are trading lower after Williams Trading downgraded the stock from Hold to Sell.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 2:09 pm

RRC

In the last 3 months, 19 analysts have offered 12-month price targets for Range Resources (NYSE:RRC), with an average price target of $31.26, a high of $40.00, and a low of $20.00. The average price target has increased by 4.51% over the past month.

Portfolio Pulse from Benzinga Insights

May 22, 2023 | 2:09 pm

FL

Deutsche Bank analyst Gabriella Carbone maintains a Hold rating on Foot Locker (NYSE:FL) and lowers the price target from $42 to $28.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 2:08 pm

GOOGL

A whale has taken a bearish stance on Alphabet (NASDAQ:GOOGL), with 64% of detected unusual options trades being bearish. Whales have been targeting a price range of $90 to $130 for Alphabet over the last 3 months. The stock is currently up 2.31% at $125.6, with RSI indicators suggesting it may be overbought.

Portfolio Pulse from Benzinga Insights

May 22, 2023 | 2:08 pm

MIRM

Mirum Pharmaceuticals (NASDAQ:MIRM) has received 7 bullish analyst ratings in the last quarter, with an average price target of $67.0, compared to its current price of $26.7517. The average price target has decreased by 19.76% from the previous average of $83.50.

Portfolio Pulse from Benzinga Insights

May 22, 2023 | 2:07 pm